Eindhoven University of Technology (TUe, www.tue.nl) is the world’s best-performing research university in terms of research cooperation with industry (#1 since 2009) and a world-leading university in engineering science and technology.
Electromagnetic Compatibility (EMC) research is a pillar of EES (Electrical energy System) group within the Electrical Engineering Faculty. We develop advanced modeling and measurement techniques that will help the designers of electronic systems to fully understand and simulate the key factors leading to potential degradation of signals in their systems at an early stage of the design process. The research focus ranges from “small” systems (e.g. noise propagation in integrated circuits) up to “large” ones (e.g. lightning protection of aircrafts). The innovative modeling and measurement techniques are rooted in advanced analytical electromagnetics, statistical electromagnetics and simulation techniques.
The University of Twente is a public university in the Netherlands with a primary focus on Engineering and with considerable experience in training through research. Together, 3300 scientists and professionals carry out ground-breaking research, bring about high technological innovation, and provide inspiring teaching for more than 10,000 students. The university has the nickname of ‘The Entrepreneurial University’, and has generated over 750 new companies in the last 3 decades. The campus is home to around 100 businesses, including student-run businesses. The EMC group performs research in EMC with a focus on measurement techniques, preventing EMI and EMC in complex (mission-critical) systems.
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of € 19.5 billion and employs approximately 80,500 employees with sales and services in more than 100 countries. In a total addressable market estimated at over EUR 140 billion, Philips is well positioned to leverage advanced technology and our deep clinical and consumer insights to deliver integrated solutions that improve people’s health and enable better outcomes across the health continuum.
In 2019, Philips invested EUR 1.88 billion in Research and Development, or 10% of sales. Nearly 12,500 employees are working in Research & Development, which is over 15% of the total work force.
KU Leuven (http://www.kuleuven.be) is the largest university in Belgium and a LERU Charter member. It had > 540 European research projects in FP7 (2007-2013), and was 6th in the league of HES institutions participating in FP7. In Horizon 2020, KU Leuven currently has more than 330 approved projects, and is in 11th place for European institutions hosting ERC grants. To date, >100 ERC Grantees confirm that KU Leuven is a breeding ground (55 Starting Grants) and attractive destination for the world’s best researchers. The success in the FP7 and Horizon 2020 Marie Skłodowska Curie Actions, with 73 (I/E)TN, is a manifestation of the three pillars of KU Leuven: research, education and service to society.
The M-Group KU Leuven supervisors (http://iiw.kuleuven.be/Bruges/groep-m/) are leading experts in dependable mechatronic systems. Key competences include mission- and safety-critical systems, fault-tolerant design, software coding, EMC, sensor networks as well as machine systems and control.
Doctoral training is provided in the framework of the Leuven Arenberg Doctoral School (https://set.kuleuven.be/phd). To assist ESRs in matters of work permits, visas, living, mobility, housing, etc., KU Leuven has the International Admissions Office (an Official Marie Skłodowska Curie mobility centre recognized by the Flemish government) with dedicated officers that offers new colleagues HR, recruitment and career- management support – www.kuleuven.be/welcome). For support in administration and finances an EU team (www.kuleuven.be/eu/contact) with 14 full-time employed experts to support with legal/financial/administrative/HR/ matters which in their can turn to a team of >50 people (including lawyers, accountants, IPR experts, etc.) for assistance at LRD TTO.
The Universitat Politècnica de Catalunya · BarcelonaTech (UPC) is a public institution of research and higher education, specializing in the fields of architecture, science, engineering and technology.
The UPC is the Spanish technical university with the highest percentage of graduate doctors. Is structured in 10 campuses, 21 schools and faculties and 30 departments. Currently offers 70 undergraduate programs, 73 master programs and 48 doctoral programs. The UPC has 58200 Alumni. The UPC figures for year 2017 are: 30.155 students, 3.093 teaching and research staff, 1.967 UPC staff, 52 patents, 61.5 million euros R&D income, 166 European projects, 515 national and regional projects, 4796 scientific publications, 359 PhD Thesis, 2 spin-off and 8 start-up. . The UPC Budget for 2018 is 283 million euros.
The ETERNITY ESRs will get their technical supervision and training in the Electromagnetic Compatibility Group (GCEM). GCEM is part of the Electronic and Biomedical Instrumentation research group of the Department of Electronic Engineering at the Universitat Politècnica de Catalunya (UPC). GCEM is formed by a team of researchers and highly qualified technical staff who are actively involved in applied research projects and technology transfer activities to the industrial sector. The group focuses its activity on electromagnetic compatibility (EMC) innovation projects. GCEM main research areas are: Near field measurement, Radiated transient measurements, time domain measurements and Numerical simulation for EMC. In the automotive, aerospace, electro- medical and EMC instrumentation areas.
Part of the training team belongs also to the instrumentation and e-health division of Research Centre for Biomedical Engineering (CREB) of UPC a centre that has been serving the needs of research, technological development, innovation and knowledge transfer of companies, hospitals and institutions related to the field of Health technologies since 1983. The CREB’s multidisciplinary staff includes more than 80 researchers, organized in seven research areas. The doctoral training is provided in the framework of the UPC doctorate school (https://doctorat.upc.edu/).
FICOSA Our company was founded in 1949. Our head office is located in Barcelona (Spain) and we have production centres, engineering centres and sales offices in 16 countries in Europe, North America, South America, and Asia. We currently have a team of more than 10,000 employees. We are a top-tier global provider devoted to the research, development, manufacturing, and marketing of advanced technology vision, safety, connectivity, and efficiency systems for the motor and mobility sectors. Our desire is to contribute to society through a commitment to technological innovation, human values, and energy efficiency. Our commitment to technology and innovation has made us pioneers in safety, connectivity, and efficiency systems for the motor sector, through research, development, and manufacturing.
Our Mission is to innovate, develop, manufacture, and create high-technology solutions to improve safety, efficiency and connectivity, always based on our commitment to our customers, partners, employees, and society as a whole and with respect for the environment. Our goal is to contribute globally to creating a better future that is safer and more sustainable for everyone, through innovation in the motor industry. The values that convey the essence of our company; how we think and believe we should act are: Interest in people, Customer focus, Teamwork / Learning together, Honesty and integrity, Commitment and passion, Leadership, and Innovation and creativity.
Plasmacure is start-up that develops and commercializes cold atmospheric plasma for would healing. Founded in 2014, expected market introduction of PLASOMA for diabetic foot ulcers in 2020.
Around ten million patients in Europe develop diabetic foot, venous leg and pressure ulcers. For 3% of diabetic foot patients these wounds result in an amputation. This decreases quality of life for patients. Our goal is to prevent this and heal wounds with Plasoma. It is a chronic wound healing device consisting of an electronic pad that creates a cold plasma in the wound and a pulser that sends the electric current to the pad. When applied to the wound the cold plasma kills the bacteria and stimulates healing.
The UMC Utrecht Center for Image Sciences (CIS) is a worldwide, leading center for translational medical imaging and image analysis for personalised image-guided diagnosis and therapy. The center focuses on medical imaging, image-guided therapy and non-invasive studies to image and monitor regenerative diseases and cancer. Currently, approximately 140 PhD students are involved in the basic and clinical science activities of the center, comprising mathematicians, physicist, chemists, biologists, medical technologists, clinical scientists and physicians. The center collaborates with several private partners (Philips Healthcare, Elekta) and small/medium enterprises, some of which are spinoffs of the research activities of the center (Quirem Medical, MRcoils BV). The High Field MR research group, headed by dr. Dennis Klomp in the UMCU CIS is focused on the development and clinical application of new ultra high field MRI techniques. This multi-disciplinary group of scientists works on mathematical modelling of nuclear spin dynamics, design and building of RF and gradient coils, pulse sequence development as well as clinical evaluation of new MRI technology in patients and volunteers.
Eurofins provides high standard quality assurance and control services, such as testing, certification, inspection, audits, technical and regulatory services, worldwide, to: Manufacturers, Brand owners, Distributors and trading companies, Buying associations, Consumer associations, Retailers…
Our laboratories provide international safety testing requested for active medical devices according to IEC 60601-xx standards family including test reports and certificates according to CB Scheme and ILAC accreditation. The competence of our labs is continuously supervised by regular inspections of IEC Assessors and other competent Authorities
In our scope (non-exhaustive list):
- Medical EMC testing performed by our labs is typically to IEC 60601-1-2 for most devices.
- Additions and/or deviations to the requirements of IEC 60601-1-2, as published in the appropriate IEC 60601-2-xx and IEC/ISO 80601-2-xx for particular devices and IEC 60601-1-xx for collateral standards
- IEC 61326 series
- ANSI ISO 14708-3- Implantable neurostimulators
- Magnetic fields FDA requirements
- Notified Body for Radio Equipment Directive (RED)2014/53/EU
- TCB (Telecommunication Certification Body) for USA and FCB (Foreign Certification Body) for Canada
- GS-Body authorized for granting GS-Mark (Geprüfte Sicherheit)
- NCB (National Certification Body) within the IECEE CB-Scheme
- KBA/NSAI recognized technical service
Hospital CIMA has a Clinical Research Unit that is part of a global project of Sanitas Hospitals, whose main purpose is to promote and encourage the development of quality research in both Hospitals and Medical Centers of the Company, with the highest standards of excellence. Currently, clinical trials of the pharmaceutical industry and research projects are being carried out internally or in collaboration with other groups. It should be highlighted the Clinical Trials Unit of the Rheumatology Service, leader in the trial of new treatments for rheumatological diseases. Hospital Sanitas CIMA, of Barcelona, will create its new Advanced Oncological Radiotherapy Center. This new facility, which will open its doors from the second quarter of 2019, will house the Oncology Care and Advice Unit, diagnostic imaging systems and the Oncology Radiation Therapy Center, equipped with TrueBeam STx linear accelerators. The CIMA Hospital has a Clinical Research Ethics Committee (CEIC) accredited by the Department of Health of the Generalitat de Catalunya, which ensures an investigative activity governed by scrupulous professional ethics.
Faculty of Sciences and Technology (NOVA-FCT), is one of the most prestigious Portuguese engineering and science public graduate schools and it is engaged in extensive research activity 5 developed in 16 research centres. One main departments of FCT will be involved in the project: Laboratory for Instrumentation, Biomedical Engineering and Radiation Physics (LIBPhys). The R&D activities of LIBPhys develop in three institutions (University NOVA of Lisbon, University of Lisbon and University of Coimbra) in the areas of atomic, molecular, nuclear physics and electronic & industrial automation instrumentation with applications to analytical methods, radiation detection and biomedical engineering. In the last 5 years, the Biomedical Engineering group of the LIBPhys published more than 40 articles in ISI international journals, was responsible for 3 PhD thesis, and established collaborations with several companies and hospitals.
Barco nv is a global technology company that designs, develops and manufactures visualization solutions for a variety of selected professional markets: control rooms, digital cinema, healthcare, media & entertainment and simulation & virtual reality. In these markets Barco offers user-friendly imaging products that optimize productivity and business efficiency. Its innovative hard- and software solutions integrate all aspects of the imaging chain, from image acquisition and processing to image display and management. Barco has its own facilities for Sales & Marketing, Customer Support, R&D and Manufacturing in Europe, North America and Asia Pacific. Barco (NYSE Euronext Brussels: BAR) is active in more than 90 countries with about 3500 employees worldwide.
Established in 2007, PLUX creates innovative products for Healthcare and Research, by developing advanced biosignal monitoring platforms that integrate wearable body sensors such as electromyography, electrocardiography, respiration, accelerometers, and others, combined with wireless connectivity and software applications to deliver real value recognized by our target markets. PLUX has a significant track record in the creation of innovative added-value products, examples of which include the work on novel technologies for physical rehabilitation (http://www.physioplux.com) and ergonomics (http://www.ergoplux.com). The latest success case is BITalino, (http://www.bitalino), which in little over three years gathered a 3300+ user base scattered across more than 40 countries worldwide.
Our mission as company is to create miniaturized sensors and wearable devices for biosignal acquisition and processing. All products aim to provide users with maximum comfort and safety, together with user-friendly software. Given the strong partnerships established with other scientific institutions, PLUX sets the bridge between the academic mean and the market, by applying and projecting the research know-how to problems and practical needs, in several technological areas.
From high know-how on analog-digital filtering and amplification electronics, PLUX can provide the acquired signals with very low noise, high sensitivity and high immunity to electronic interferences. Currently we have a set of biomedical sensors such as Electrocardiography (ECG), Electromyography (EMG), Electrodermal Activity (EDA), respiration, accelerometer and others, from which several physiological parameters can be extracted, such as: heart rate (HR), heart rate variability (HRV), muscle activation (EMG), sympathetic events from EDA sensors or energy expenditure from an accelerometer. Beyond biomedical sensors, PLUX also has expertise in hardware development, enabling the quick turnaround and discovery of new solutions, new applications and market-focused strategies in the field of biosignal sensing.